Introduction {#sec1-1}
============

Vitiligo is a common, chronic, acquired cutaneous de-pigmentation disorder with *serious emotional* and *psychological consequences* \[[@ref1]\], \[[@ref2]\]. There are many possible conventional or unconventional therapeutic choice for the treatment \[[@ref3]\], \[[@ref4]\]. Narrow-band ultraviolet B (NB-UVB) is one of the best treatment modality for vitiligo because of its safety, effectiveness and non-evasive nature, promoting stabilisation of the depigmenting process and stimulation of residual follicular melanocytes \[[@ref5]\].

The present study aims to examine the efficacy and safety of NB-UVB therapy in Vietnamese vitiligo patients, attending the Vietnam National Hospital of Dermatology and Venereology from October 2016 to September 2017.

Methods {#sec1-2}
=======

A total of 31 vitiligo patients (14 males, 17 females; 28 with Fitzpatrick skin's type IV and only 3 patients with Fitzpatrick skin's type III), mean age 30 years old. The majority of patients (29/31) had NSV, and only 2 patients had SV.

Local NB-UVB 311 nm irradiation was indicated for vitiligo patients with 2% and less than 2% body surface involved (12 patients). Whole body NB-UVB 311 nm irradiation was indicated for those with more than 2% body surface involved (19 patients). Patients were treated with thrice-weekly exposures on non-consecutive days. The starting dose for adults from 15 years old and children less than 15 years old was 200 mJ/cm^2^ and 150 mJ/cm^2^, respectively, with 50 mJ/cm^2^ and 20 mJ/cm^2^ dose increments at each subsequent visit, respectively, until mild erythema lasting less than 24 hrs reported by patient, given for a period of 6 months. The response to NB-UVB therapy was examined based on changes of vitiligo area severity index (VASI) after treatment, which took into account of both percentage of re-pigmentation and the reduction of lesion's area \[[@ref6]\].

Results {#sec1-3}
=======

After 6-month treatment, 38.7% obtained a very good response, 41.9% patients achieved a good response, the proportion of poor, very poor and no response was equally and accounted for only 6.5% as shown in [Figure 1](#F1){ref-type="fig"}.

![A case of 10 years old male with very good response to therapy: (a) before treatment, (b) after 2 months -VASI decreased 16.4%, (c) after 4 months - VASI decreased 58%, (c) after 6 months VASI decreased 95%](OAMJMS-7-256-g001){#F1}

Association between response to therapy and the duration of the treatment was shown in [Figure 2](#F2){ref-type="fig"}.

![Association between response to therapy and the duration of the treatment](OAMJMS-7-256-g002){#F2}

Among 31 patients, total good and very good response to therapy were significantly associated with prolonged treatment, increasing from 19.4% to 64.5% and 80.6% after 2, 4 and 6-month treatment, respectively. Association between response to therapy and localised or generalised NSV was shown in [Figure 3](#F3){ref-type="fig"}.

![Association between response to therapy and localised or generalised NSV](OAMJMS-7-256-g003){#F3}

Total good and very good response to therapy was observed in localised NSV significantly more frequently than in generalised NSV patients (55.6% versus 18.2%). This difference is statistically different.

In our study, good and very good response to therapy significantly increased with prolonged treatment and was observed in localised NSV significantly more frequently than in generalised NSV patients, which are consistent with previous studies \[[@ref7]\], \[[@ref8]\], \[[@ref9]\], \[[@ref10]\]. The actual good and very good response rate to therapy will properly be higher if the evaluation time is longer than 6 months. Adverse effects in our study were minimal which is similar to that reported in the literature.

In conclusion, our study proves that NB-UVB therapy is an effective and safe tool in the management of Vietnamese vitiligo patients. Further study is recommended to prolong the treatment duration and follow up the stability of re-pigmentation.
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